|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Phase Forward (PFWD), a provider of integrated data management software for clinical trials and drug safety. |
|---|---|
| Transferring Party | Maaguzi LLC, a provider of Web-based, electronic patient reported outcomes. |
| Sector | Data Management/ Healthcare IT |
| Date | July 27, 2009 |
| Analysis Extends Phase Forward’s clinical research suite into observational studies markets. Clinical studies are progressively incorporating data reported directly by patients, and electronic methods of collecting patient input. There is growing focus on late phase, observational studies and registries that combine investigator-collected and patient-reported data. Deal value -- $11m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |